App-Quantinova.ai

Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma

Yuji Mishima - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hematological malignancies

N/A

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Pieter Sonneveld - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte) In Adult Acute Lymphoblastic Leukemia (ALL)

Renato Bassan - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methotrexate

Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV

Rudiger Hehlmann - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Angiology

Peripheral artery disease

Imatinib

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Indatuximab ravtansine

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Ulrich Jaeger - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Rituximab

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Barbara Muz - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort

Louis Terriou - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Mycophenolate mofetil

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

Diego Alignani - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Multiple Myeloma

N/A

Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM)

Bruno Paiva - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Trastuzumab

MONTHLY IBANDRONATE REDUCES BONE LOSS IN OSTEOPENIC WOMEN WITH RHEUMATOID ARTHRITIS RECEIVING LONG-TERM GLUCOCORTICOIDS: A 48-WEEK DOUBLE-BLINDED RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR-INITIATED TRIAL

K. Shin - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

cholecalciferol

Ultrasound in The Management of Rheumatoid Arthritis: Results from The Randomized Controlled Arctic Trial

E.A. Haavardsholm - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Platelets, Tumor Cell Invasiveness, and Metastasis

Richard O. Hynes - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Howard Liebman - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Immune thrombocytopenia

HA20

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Stefan O Schonland - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

AL Amyloidosis

Dexamethasone

TRABECULAR BONE SCORE IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS AND CHANGES DURING LONG TERM TREATMENT WITH TNFA BLOCKING AGENTS

E. Toussirot - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

N/A

RESULTS FROM THE RATE-RA STUDY: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF ADMINISTERING RITUXIMAB AT A MORE RAPID INFUSION RATE IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. H. Pritchard - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methylprednisolone

MICROARCHITECTURE ASSESSMENT BY TRABECULAR BONE SCORE AT THE SPINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS. PRELIMINARY RESULTS

E. Toussirot - European League Against Rheumatism (EULAR) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

N/A

LONG-TERM SAFETY OF RITUXIMAB: 10-YEAR FOLLOW-UP IN THE RHEUMATOID ARTHRITIS GLOBAL CLINICAL TRIAL PROGRAMME

R.F. van Vollenhoven - European League Against Rheumatism (EULAR) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cardiorenal syndrome

Methotrexate

Molecular characterization of the tumour microenvironment in neuroendocrine malignancy.

David James Pinato - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

1671 Abstracts